RICHMOND, British Columbia, July 13, 2005 (PRIMEZONE) -- BioCurex Inc. (Pink Sheets:BOCX) announced today the publication of its tissue and serum RECAF results in the last issue (June) of the journal IVD Technology (IVD is an acronym for In-Vitro Diagnostics, meaning clinical studies done on samples in a test tube).
The article was initially requested by IVDT in 2003 and it was originally limited to the detection of cancer cells on tissue sections. Publication was then postponed in order to include the results obtained on serum samples. The article's title is "A new broad-spectrum cancer marker."
IVDT has a circulation of 15,000 mostly among professional personnel in product R&D, design, manufacturing, quality assurance, regulatory affairs, and corporate management. All manuscripts are subjected to double-blind peer review to ensure the quality and relevance of the materials. The publisher disallows promotion of brands, products or services offered by authors.
In addition to the IVDT article, Hematology Oncology News & Issues interviewed Dr. Moro (BioCurex's CEO) and as a result it published, in its May 2005 issue, a commentary on RECAF entitled: "RECAF biomarker for common cancers provides patient, doctor benefits."
An excerpt of the article reads: "RECAF technology has the potential to benefit patients, doctors and the health care system by ruling out unnecessary and sometimes painful, biopsies; allowing oncologists to react promptly to elevated RECAF presence; and diagnosis patients at earlier stages."
Hematology Oncology News & Issues is a NEWS magazine. Its charter is to report on the latest developments in these medical specialties and provide a forum for the exchange of ideas among the professional disciplines responsible for delivering care to the cancer patient.
Also, the May issue of "View on Biotechnology," a supporting publication to Pharmavoice, which reaches 17,000 U.S.-based life-sciences executives, dedicated its May issue to: "Thought Leader Perspective. An overview of the biotechnology industry." Dr. Moro was one of the 16 "thought leaders" interviewed.
None of the publications was paid for space, nor does BioCurex advertise in any of them. Links to the above-mentioned publications can be found in the News section of the company's Web site (www.biocurex.com).
Dr. Moro, President & CEO of BioCurex stated: "In the current business environment it is necessary but not sufficient to have an excellent technology; success ultimately depends on people -- from the general public to industry leaders -- learning about it. We are very glad to see the blood and tissue test results published in a peer reviewed publication that reaches not only scientists but also industry leaders.
"We are well aware of the importance of communicating our results and achievements in many different forums including journals, congresses and industry magazines. These publications, together with the invitations we have received to discuss our results in the upcoming ISOBM congress suggest that people in our field are starting to take notice of our achievements. We shall continue our efforts in that direction."
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To read more about the Company, please visit the News section in our web site (www.biocurex.com).
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.